[COPD and Clinical Trials. Results of an expert meeting "Castles in the Air" 2010]. / COPD und Studien. Ergebnisse des Expertentreffens Luftschlösser 2010, Mainz, 3.4. Dezember 2010 (Sponsor: Boehringer Ingelheim Pharma GmbH & Co KG).
Pneumologie
; 65(7): 436-48, 2011 Jul.
Article
en De
| MEDLINE
| ID: mdl-21656462
ABSTRACT
Clinical trials in COPD patients aim at achieving progress in diagnosis and treatment. Study results should be applicable to a large number of patients. However, an analysis of the methods and design of current and previous trials reveals considerable room for improvement. COPD is a complex disease with different clinical phenotypes. Genetic factors need to be evaluated systematically to allow appropriate stratification of patients. Frequently used endpoints such as the FEV1 that had previously been considered reliable have shown limitations in recent trials. Thus, researchers now aim to identify new surrogate parameters that are related to the prognosis of the disease, e.âg., composite endpoints and biomarkers. Physical activity and capacity are becoming increasingly important for the evaluation of disease progression. The focus of pharmaceutical development is long acting bronchodilators and new anti-inflammatory drugs. The value of non-drug interventions will also be evaluated.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neumología
/
Ensayos Clínicos como Asunto
/
Enfermedad Pulmonar Obstructiva Crónica
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
De
Revista:
Pneumologie
Año:
2011
Tipo del documento:
Article